Pet Pharm Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	321.49	181.79	168.49	16.76
Cash & Short-Term Investments	571.69	181.79	168.49	16.76
Cash Growth	3311.85%	7.89%	905.52%	-
Receivables	41.59	33.78	31.24	20.91
Inventory	9.24	13.68	10.8	5.81
Other Current Assets	4.36	212.69	143.88	54.84
Total Current Assets	629.73	441.93	354.4	98.31
Property, Plant & Equipment	343.78	290.2	92.45	84.57
Other Intangible Assets	8.19	9.08	4.05	5.08
Long-Term Deferred Tax Assets	2.09	2.09	-	-
Other Long-Term Assets	120.78	16.76	36.67	3.93
Total Assets	1,105	760.06	487.58	191.89
Accounts Payable	1.48	7.92	4.81	2.91
Current Portion of Leases	8.04	6.42	6.57	4.58
Current Unearned Revenue	3.96	4.31	3.94	3.09
Other Current Liabilities	29.69	121.41	16.99	8.88
Total Current Liabilities	143.17	140.05	32.31	19.46
Long-Term Leases	65.99	37.46	41.63	37.94
Total Liabilities	209.53	177.52	73.94	57.4
Common Stock	505.29	405.29	371.9	251.9
Additional Paid-In Capital	368.72	78.72	150.01	-
Retained Earnings	9.98	14.51	-108.27	-117.42
Comprehensive Income & Other	11.03	84.03	-	-
Shareholders' Equity	895.03	582.54	413.64	134.48
Total Liabilities & Equity	1,105	760.06	487.58	191.89
Total Debt	174.02	43.88	48.2	42.52
Net Cash (Debt)	397.67	137.91	120.29	-25.77
Net Cash Growth	-	14.65%	-	-
Net Cash Per Share	8.56	3.38	4.02	-1.07
Filing Date Shares Outstanding	51.21	40.84	29.91	24.13
Total Common Shares Outstanding	51.21	40.84	29.91	24.13
Working Capital	486.56	301.88	322.1	78.85
Book Value Per Share	17.48	14.27	13.83	5.57
Tangible Book Value	886.84	573.47	409.59	129.4
Tangible Book Value Per Share	17.32	14.04	13.69	5.36

Source: S&P Global Market Intelligence. Standard template. Financial Sources.